NYSE:HQL Tekla Life Sciences Investors Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tekla Life Sciences Investors Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $17.25 -0.49 (-2.76 %) (As of 09/21/2020 12:00 AM ET) Add Compare Share Today's Range$17.12Now: $17.25▼$17.6350-Day Range$16.71MA: $17.65▼$18.4052-Week Range$11.45Now: $17.25▼$19.28Volume62,718 shsAverage Volume106,070 shsMarket Capitalization$392.54 millionP/E RatioN/ADividend Yield8.29%Beta1.18 ProfileChartCompetitorsDividendFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Tekla Life Sciences Investors. Previous Next 2.6 Community Rank Outperform VotesTekla Life Sciences Investors has received 93 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTekla Life Sciences Investors has received 89 “underperform” votes. (Add your “underperform” vote.)Community SentimentTekla Life Sciences Investors has received 51.10% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Tekla Life Sciences Investors and other stocks. Vote “Outperform” if you believe HQL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HQL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 1.7 Dividend Strength Dividend LeadershipTekla Life Sciences Investors is a leading dividend payer. It pays a dividend yield of 8.29%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthTekla Life Sciences Investors has only been increasing its dividend for 1 years. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tekla Life Sciences Investors insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.06% of the stock of Tekla Life Sciences Investors is held by insiders.Percentage Held by InstitutionsOnly 17.59% of the stock of Tekla Life Sciences Investors is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.85 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Investment offices, not elsewhere classified Sub-IndustryN/A SectorFinance Current SymbolNYSE:HQL Previous Symbol CUSIPN/A CIK884121 Webwww.teklacap.com Phone617-772-8500Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares22,756,000Market Cap$392.54 million Next Earnings DateN/A OptionableNot Optionable $17.25 -0.49 (-2.76 %) (As of 09/21/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive HQL News and Ratings via Email Sign-up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter. Tekla Life Sciences Investors (NYSE:HQL) Frequently Asked Questions How has Tekla Life Sciences Investors' stock been impacted by COVID-19 (Coronavirus)? Tekla Life Sciences Investors' stock was trading at $14.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HQL shares have increased by 16.2% and is now trading at $17.25. View which stocks have been most impacted by COVID-19. How often does Tekla Life Sciences Investors pay dividends? What is the dividend yield for Tekla Life Sciences Investors? Tekla Life Sciences Investors announced a quarterly dividend on Tuesday, August 18th. Investors of record on Friday, August 28th will be given a dividend of $0.41 per share on Wednesday, September 30th. This represents a $1.64 annualized dividend and a dividend yield of 9.51%. The ex-dividend date of this dividend is Thursday, August 27th. This is an increase from Tekla Life Sciences Investors's previous quarterly dividend of $0.34. View Tekla Life Sciences Investors' dividend history. Are investors shorting Tekla Life Sciences Investors? Tekla Life Sciences Investors saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 85,000 shares, an increase of 135.5% from the August 15th total of 36,100 shares. Based on an average daily volume of 82,700 shares, the short-interest ratio is currently 1.0 days. View Tekla Life Sciences Investors' Short Interest. Who are some of Tekla Life Sciences Investors' key competitors? Some companies that are related to Tekla Life Sciences Investors include PIMCO Corporate&Income Opportunity Fund (PTY), Direxion Daily Financial Bull 3X Shares (FAS), Tri-Continental (TY), Gabelli Equity Trust (GAB), Hercules Capital (HTGC), Royce Value Trust (RVT), Liberty All-Star Equity Fund (USA), iShares MSCI Australia ETF (EWA), iShares, Inc. - iShares MSCI Hong Kong ETF (EWH), Boulder Growth & Income Fund (BIF), Aberdeen Asia-Pacific Income Fund (FAX), AllianceBernstein Global Hgh Incm Fd (AWF), SPDR Bloomberg Barclays International Treasury Bond ETF (BWX), Blackrock Muniyield Insured Fund (MYI) and Tekla Healthcare Investors (HQH). View all competitors. What other stocks do shareholders of Tekla Life Sciences Investors own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tekla Life Sciences Investors investors own include NVIDIA (NVDA), Energy Transfer LP Unit (ET), QUALCOMM (QCOM), AT&T (T), Enbridge (ENB), IBM (IBM), Kinder Morgan (KMI), Main Street Capital (MAIN), Pfizer (PFE) and Weyerhaeuser (WY). Who are Tekla Life Sciences Investors' key executives? Tekla Life Sciences Investors' management team includes the following people: Dr. Daniel R. Omstead M.S, Ph.D., Principal Exec. Officer, Pres and Trustee (Age 66)Ms. Laura F. Woodward, Principal Financial Officer, Chief Compliance Officer, Sec. and Treasurer (Age 51)Ms. Betty T. Chang, Assistant Treasurer (Age 47) What is Tekla Life Sciences Investors' stock symbol? Tekla Life Sciences Investors trades on the New York Stock Exchange (NYSE) under the ticker symbol "HQL." Who are Tekla Life Sciences Investors' major shareholders? Tekla Life Sciences Investors' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Matisse Capital (1.42%), Flagship Harbor Advisors LLC (1.25%), Advisors Asset Management Inc. (1.17%), Advisor Group Holdings Inc. (0.55%), RMB Capital Management LLC (0.42%) and UBS Group AG (0.41%). View institutional ownership trends for Tekla Life Sciences Investors. Which major investors are selling Tekla Life Sciences Investors stock? HQL stock was sold by a variety of institutional investors in the last quarter, including Karpus Management Inc., Karpus Management Inc., RMB Capital Management LLC, Bank of America Corp DE, Mid Atlantic Financial Management Inc. ADV, 180 Wealth Advisors LLC, Janney Montgomery Scott LLC, and Raymond James Financial Services Advisors Inc.. View insider buying and selling activity for Tekla Life Sciences Investors. Which major investors are buying Tekla Life Sciences Investors stock? HQL stock was bought by a variety of institutional investors in the last quarter, including Matisse Capital, UBS Group AG, Advisors Asset Management Inc., AE Wealth Management LLC, Sawtooth Solutions LLC, CNH Partners LLC, Vanguard Capital Wealth Advisors, and Live Oak Private Wealth LLC. View insider buying and selling activity for Tekla Life Sciences Investors. How do I buy shares of Tekla Life Sciences Investors? Shares of HQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Tekla Life Sciences Investors' stock price today? One share of HQL stock can currently be purchased for approximately $17.25. How big of a company is Tekla Life Sciences Investors? Tekla Life Sciences Investors has a market capitalization of $392.54 million. What is Tekla Life Sciences Investors' official website? The official website for Tekla Life Sciences Investors is www.teklacap.com. How can I contact Tekla Life Sciences Investors? Tekla Life Sciences Investors' mailing address is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. The company can be reached via phone at 617-772-8500 or via email at [email protected] This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
